Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 475-482

  Thompson, Nia ^a   Nazir, Niaman ^a   Cox, Lisa Sanderson ^a,b   Faseru, Babalola ^a,b   Goggin, Kathy ^c   Ahluwalia, Jasjit S ^d   Nollen, Nicole L ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

African Americans; Medication adherence; Smoking cessation

Indexed keywords

VARENICLINE;

ADULT; AFRICAN AMERICAN; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; FEMALE; HEALTH CARE MANAGEMENT; HUMAN; LOWEST INCOME GROUP; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; UNANNOUNCED TELEPHONE PILL COUNT;

EID: 84866515524     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S24023     Document Type: Article

References (48)

1. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008;57(45):1226-1228.
2. Fiore M, Jaen C, Baker T, et al. Treating Tobacco Use and Dependence Clinical Practice Guideline: 2008 Update. Washington, DC: US Department of Health and Human Services; 2008. Available at: http://www. surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
3. Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6): 574-581.
4. Fish LJ, Peterson BL, Namenek Brouwer RJ, et al. Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res. 2009;11(5):514-518.
5. Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: a replication and extension study. Addict Behav. 2007;32(4):875-880.
6. Shiffman S, Sweeney CT, Ferguson SG, Sembower MA, Gitchell JG. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, doubleblind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther. 2008;30(10):1852-1858.
7. Catz SL, Jack LM, McClure JB, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361-368.
8. Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting. Am J Health Behav. 2004;28(4):291-301.
9. Nollen NL, Cox LS, Nazir N, et al. A pilot clinical trial of varenicline for smoking cessation in Black smokers. Nicotine Tob Res. 2011. [Epub ahead of print.]
10. Nyfort-Hansen K NM, Parthasarathi G, Nahata K, Milap C. A Text Book of Clinical Pharmacy Practice: Essential Concepts and Skills. Hyderabad, India: Orient Blackswan; 2004.
11. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
12. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090; discussion 1073.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
14. Noncompliance with medication regimens. An economic tragedy. Emerging issues in pharmaceutical cost containing. Washington, DC: National Pharmaceutical Council; 1992:1-16.
15. Kim HM, Lagakos SW. Assessing drug compliance using longitudinal marker data, with application to AIDS. Stat Med. 1994;13(19-20): 2141-2153.
16. van Onzenoort HAW, Verberk WJ, Kessels AGH, et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. Am J Hypertens. 2009;23(2):149-154.
17. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, selfreport, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32(7-8):749-754.
18. Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: Electronic medication monitors and unannounced pill counts. AIDS and Behavior. 2001;5(3):275-281.
19. Kalichman SC, Amaral CM, Cherry C, et al. Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials. 2008;9(5): 298-308.
20. Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22(7):1003-1006.
21. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
22. Okuyemi KS, Zheng H, Guo H, Ahluwalia JS. Predictors of adherence to nicotine gum and counseling among African-American light smokers. J Gen Intern Med. 2010;25(9):969-976.
23. Cancer Prevention and Control Program University of California San Diego. The California Tobacco Control Program: A Decade of Progress, Results from the California Tobacco Survey, 1990-1999; Final Report. La Jolla, CA: California Department of Health Services Tobacco Control Section; 1999. Available from: http://libraries.ucsd.edu/ssds/pub/CTS/ cpc00006/1999_Final_Report.pdf. Accessed September 13, 2011.
24. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789-1795.
25. Gomez A, Conde A, Santana H, Jorrin A. Diagnostic usefulness of briefer versions of alcohol use disorders identification test (AUDIT) for detecting hazardous drinkers in primary care settings. J Stud Alcohol. 2005;66(2):305-308.
26. Cole J, Rabin A, Smith T, Kaufman A. Development and validation of a Rasch-derived CES-D short form. Psychological Assessment. 2004;16(4):360-372.
27. Ahluwalia JS, Okuyemi K, Nollen N, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 aa2 factorial design. Addiction. 2006;101(6):883-891.
28. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustainedrelease bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002;288(4):468-474.
29. Resnicow K, Jackson A, Wang T, et al. A motivational interviewing intervention to increase fruit and vegetable intake through Black churches: results of the Eat for Life trial. Am J Public Health. 2001;91(10):1686-1693.
30. Rollnick S, Butler C, Stott N. Helping smokers make decisions: The enhancement of brief interventions for general medical practice. Patient Educ Couns. 1997;31(3):191-203.
31. Amrhein PC, Miller WR, Yahne CE, Palmer M, Fulcher L. Client commitment language during motivational interviewing predicts drug use outcomes. J Consult Clin Psychol. 2003;71(5):862-878.
32. Catley D, Gerkovich M, Williams K, Goggin K. A 4-item measure of motivation to adhere that predicts MEMS adherence over 48 weeks. Paper presented at: NIMH/IAPAC International Conference on HIV Treatment Adherence 2010, May 23-25, Miami, FL.
33. Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). J Behav Med. 2007;30(5):359-370.
34. Wallston K, Malcarne V, Flores L, et al. Does God determine your health? The God Locus of Health Control scale. Cognitive Therapy and Research. 1999;23(2):131-142.
35. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised openlabel trial. Thorax. 2008;63(8):717-724.
36. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
37. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;29(6):1040-1056.
38. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008;24(7):1931-1941.
39. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561-1568.
40. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571-1577.
41. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
42. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027-1039.
43. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009;14(3):384-392.
44. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
45. Toll BA, McKee SA, Martin DJ, Jatlow P, O'Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine Tob Res. 2007;9(5):597-605.
46. Balmford J, Borland R, Hammond D, Cummings KM. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94-102.
47. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007;45(7):908-915.
48. Schoenthaler A, Ogedegbe G. Patients' perceptions of electronic monitoring devices affect medication adherence in hypertensive African Americans. Ann Pharmacother. 2008;42(5):647-652.